Navigation Links
Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference
Date:2/22/2011

PRINCETON, N.J., Feb. 22, 2011 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today announced that it will present at the 2nd Annual Morningstar/NYSSA Healthcare Conference on Thursday, February 24, 2011 at 10:00 a.m. ET.  Investors may access a live webcast of the presentation at www.covance.com.  In order to register and download any necessary software, please log on 10 minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.9 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release (and in the webcast announced in this press release), which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
2. Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56
3. Covance Reports Third Quarter Financial Results and Takes Actions to Strengthen Future Performance
4. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
5. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
6. Covance Board Authorizes $250 Million Stock Buyback
7. Covance to Present at Morgan Stanley Global Healthcare Conference
8. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
9. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
10. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
11. Covance To Present At The 20th Annual Global Healthcare Services Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... According to a new market ... by Type (Human, Animal Pathology), by End User (Pharmaceutical ... - Global Forecasts to 2021", published by MarketsandMarkets, studies ... of 2016 to 2021. This market is expected to ... Million in 2016, at a CAGR of 12.1%. ...
(Date:5/31/2016)... May 31, 2016 Aloe vera ... food, cosmetics and pharmaceuticals, with global volume to surpass ... 1.6 Bn. Demand for aloe vera extracts ... yogurts will continue its upward momentum in 2016 as ... boost positive sentiment on aloe vera, with wide-ranging applications ...
(Date:5/31/2016)... , May 31, 2016 ... World Health Assembly zur Eliminierung von viraler Hepatitis ... Mitgliedsstaaten eine historische Verpflichtung eingegangen, virale Hepatitis bis ... . World Health Assembly haben sich die ... bzgl. viraler Hepatitis (Global Viral Hepatitis Strategy) zu ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Fire Door Solutions, ... joined the Fire Door Solutions’ team. Keith will serve Fire Door Solutions ... in-field re-labeling. He will be instrumental in developing educational curriculum and leading ...
(Date:5/31/2016)... ... 31, 2016 , ... More than 80 representatives of the Hepatitis B ... Cancer Foundation held an event on National Hepatitis Testing Day outside of Philadelphia City ... the leading cause of liver cancer. , Foundation leaders and the citywide coalition they ...
(Date:5/31/2016)... TEXAS (PRWEB) , ... May 31, 2016 , ... ... live in Greater Houston Healthconnect’s (Healthconnect) regional health information exchange, which enables physicians ... medical records for their patients from other participating organizations in the exchange. SJMC’s ...
(Date:5/31/2016)... ... May 31, 2016 , ... When ... he knew it was something that contractors should have at their disposal on ... gets,” says Butch, CertainTeed’s Director of Contractor Programs. , As a result, ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spartan Bioscience today introduced ... portability and convenience. , The Cube is exceptionally small—it takes up the space ... fits easily into any space, whether in a hospital, doctor’s office, or pharmacy. ...
Breaking Medicine News(10 mins):